Information Provided By: 
Fly News Breaks for March 14, 2017
BIO
Mar 14, 2017 | 07:25 EDT
Jefferies analyst Brandon Couillard believes yesterday's updates from Bio-Rad Laboratories, which included 2020 revenue and margin goals, a capital allocation plan which opens the door to buybacks as well as board changes, make the path to $300 per share over the next few years "a lot clearer." It is time to forget everything you thought you knew about Bio-Rad, Couillard tells investors in a research note. He raised his price target for the stock to $250 from $225 and keeps a Buy rating on the name.
News For BIO From the Last 2 Days
There are no results for your query BIO
